International Journal of Clinical Oncology

, Volume 20, Issue 2, pp 273–281 | Cite as

Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance

  • Yiting Geng
  • Hui Wang
  • Changqing Lu
  • Qing Li
  • Bin Xu
  • Jingting JiangEmail author
  • Changping WuEmail author
Original Article



Immune escape plays an important role in tumor progression. In the present study, the expression of B7-H1, B7-H4 and Foxp3 involved in immune escape in gastric carcinoma was investigated and the corresponding clinical significance was evaluated.


Immunohistochemistry was used to detect the expression of B7-H1, B7-H4 and Foxp3 in 100 gastric cancer specimens, and 30 paracarcinoma tissues were used as the control.


Both B7-H1 and B7-H4 showed high expression levels in gastric cancer tissues (65.0 and 71.0 %, respectively), and the expressions of B7-H1 and B7-H4 were positively correlated with the depth of tumor invasion, lymph node metastasis and American Joint Committee on Cancer (AJCC) stage (P < 0.05). The number of Foxp3+ Tregs was much higher in gastric cancer tissues than control tissues, which was positively correlated with lymph node metastasis (P < 0.05). Similarly, a positive correlation between B7-H1 or B7-H4 expression and the number of Foxp3+ Tregs was observed. The median overall survival rate of patients with high expression of B7-H1, B7-H4 and Foxp3 was significantly poorer than that of patients with low expression of these proteins (P < 0.05). Cox regression multivariate analysis confirmed that lymph node metastasis, AJCC stage, and B7-H1 and Foxp3 overexpression were independent prognostic factors.


B7-H1, B7-H4 and Foxp3 were overexpressed in gastric cancer tissues. B7-H1 and Foxp3 are negative prognostic factors for patients with gastric cancer.


Gastric cancer B7-H1 B7-H4 Foxp3 Tregs Costimulatory molecule 



This research project was supported by the National Natural Science Foundation of China (NSFC) (81171653 and 30972703) and Natural Science Foundation of Jiangsu Province (BK2011246 and BK2011247).

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Ferrone S, Whiteside TL (2007) Tumor microenvironment and immune escape. Surg Oncol Clin N Am 16(4):755–774PubMedCrossRefGoogle Scholar
  2. 2.
    Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8(6):467–477PubMedCrossRefGoogle Scholar
  3. 3.
    Pardoll DM (2002) Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2(4):227–238PubMedCrossRefGoogle Scholar
  4. 4.
    Chen J, Li G, Meng H et al (2012) Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother 61(1):101–108PubMedCrossRefGoogle Scholar
  5. 5.
    Pan XC, Li L, Mao JJ et al (2013) Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma. Oncol Lett 5(1):90–96PubMedCentralPubMedGoogle Scholar
  6. 6.
    Zhang L, Wu H, Lu D et al (2013) The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene 32(46):5347–5358PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Wang S, Chen L (2004) Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes Infect 6(8):759–766PubMedCrossRefGoogle Scholar
  8. 8.
    Zhu G, Augustine MM, Azuma T et al (2009) B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood 113(8):1759–1767PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Ohigashi Y, Sho M, Yamada Y et al (2005) Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 11(8):2947–2953PubMedCrossRefGoogle Scholar
  10. 10.
    Zheng X, Li XD, Wu CP et al (2012) Expression of costimulatory molecule B7-H4 in human malignant tumors. Onkologie 35(11):700–705PubMedCrossRefGoogle Scholar
  11. 11.
    Gadiot J, Hooijkaas AI, Kaiser AD et al (2011) Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117(10):2192–2201PubMedCrossRefGoogle Scholar
  12. 12.
    Wu C, Zhu Y, Jiang J et al (2006) Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108(1):19–24PubMedCrossRefGoogle Scholar
  13. 13.
    Jiang J, Zhu Y, Wu C et al (2010) Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother 59(11):1707–1714PubMedCrossRefGoogle Scholar
  14. 14.
    Mailloux AW, Young MR (2010) Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit Rev Immunol 30(5):435–447PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Hori S, Sakaguchi S (2004) Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 6(8):745–751PubMedCrossRefGoogle Scholar
  16. 16.
    Gratz IK, Rosenblum MD, Abbas AK (2013) The life of regulatory T cells. Ann N Y Acad Sci 1283:8–12PubMedCrossRefGoogle Scholar
  17. 17.
    Lu X, Liu J, Li H et al (2011) Conversion of intratumoral regulatory T cells by human gastric cancer cells is dependent on transforming growth factor-beta1. J Surg Oncol 104(6):571–577PubMedCrossRefGoogle Scholar
  18. 18.
    Woo EY, Chu CS, Goletz TJ et al (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61(12):4766–4772PubMedGoogle Scholar
  19. 19.
    Wang HY, Wang RF (2007) Regulatory T cells and cancer. Curr Opin Immunol 19(2):217–223PubMedCrossRefGoogle Scholar
  20. 20.
    Association Japanese Gastric Cancer (1998) Japanese classification of gastric carcinoma—2nd English Edition. Gastric Cancer 1(1):10–24CrossRefGoogle Scholar
  21. 21.
    Hartgrink HH, Jansen EP, van Grieken NC et al (2009) Gastric cancer. Lancet 374(9688):477–490PubMedCrossRefGoogle Scholar
  22. 22.
    Yeh JM, Kuntz KM, Ezzati M et al (2009) Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer 124(1):157–166PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Zang X, Allison JP (2007) The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 13(18 Pt 1):5271–5279PubMedCrossRefGoogle Scholar
  24. 24.
    Brown JA, Dorfman DM, Ma FR et al (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170(3):1257–1266PubMedCrossRefGoogle Scholar
  25. 25.
    Choi IH, Zhu G, Sica GL et al (2003) Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 171(9):4650–4654PubMedCrossRefGoogle Scholar
  26. 26.
    Kryczek I, Zou L, Rodriguez P et al (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203(4):871–881PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Krambeck AE, Thompson RH, Dong H et al (2006) B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 103(27):10391–10396PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Tringler B, Zhuo S, Pilkington G et al (2005) B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 11(5):1842–1848PubMedCrossRefGoogle Scholar
  29. 29.
    Tringler B, Liu W, Corral L et al (2006) B7-H4 overexpression in ovarian tumors. Gynecol Oncol 100(1):44–52PubMedCrossRefGoogle Scholar
  30. 30.
    Zang X, Thompson RH, Al-Ahmadie HA et al (2007) B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 104(49):19458–19463PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Simon I, Liu Y, Krall KL et al (2007) Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol 106(1):112–118PubMedCrossRefGoogle Scholar
  32. 32.
    Thompson RH, Zang X, Lohse CM et al (2008) Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res 68(15):6054–6058PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Iwai Y, Ishida M, Tanaka Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99(19):12293–12297PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793–800PubMedGoogle Scholar
  35. 35.
    Curiel TJ, Wei S, Dong H et al (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9(5):562–567PubMedCrossRefGoogle Scholar
  36. 36.
    Prasad DV, Richards S, Mai XM et al (2003) B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18(6):863–873PubMedCrossRefGoogle Scholar
  37. 37.
    Sica GL, Choi IH, Zhu G et al (2003) B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18(6):849–861PubMedCrossRefGoogle Scholar
  38. 38.
    Zang X, Loke P, Kim J et al (2003) B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 100(18):10388–10392PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Strauss L, Bergmann C, Szczepanski M et al (2007) A unique subset of CD4+ CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13(15 Pt 1):4345–4354PubMedCrossRefGoogle Scholar
  40. 40.
    Liu J, Zhang N, Li Q et al (2011) Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One 6(4):e19495PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Loser K, Apelt J, Voskort M et al (2007) IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol 179(1):365–371PubMedCrossRefGoogle Scholar
  42. 42.
    Li Q, Chen J, Liu Y et al (2013) Prevalence of Th17 and Treg cells in gastric cancer patients and its correlation with clinical parameters. Oncol Rep 30(3):1215–1222PubMedGoogle Scholar
  43. 43.
    Li H, Yu JP, Cao S et al (2007) CD4 +CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol 27(3):317–326PubMedCrossRefGoogle Scholar
  44. 44.
    Bastid J, Cottalorda-Regairaz A, Alberici G et al (2013) ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 32(14):1743–1751PubMedCrossRefGoogle Scholar
  45. 45.
    Sun X, Wu Y, Gao W et al (2010) CD39/ENTPD1 expression by CD4 + Foxp3 + regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139(3):1030–1040PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2014

Authors and Affiliations

  1. 1.Department of OncologyThe Third Affiliated Hospital of Soochow UniversityChangzhouPeople’s Republic of China
  2. 2.Department of PathologyThe Third Affiliated Hospital of Soochow UniversityChangzhouPeople’s Republic of China
  3. 3.Department of Tumor Biological TreatmentThe Third Affiliated Hospital of Soochow UniversityChangzhouPeople’s Republic of China

Personalised recommendations